THE INFLUENCE OF AGE AND INITIAL BLOOD PRESSURE LEVELS ON BLOOD PRESSURE CONTROL AND TOLERABILITY IN HYPERTENSIVE PATIENTS UNDER SINGLE PILL FIXED-DOSE COMBINATION OF ANGIOTENSIN RECEPTOR BLOCKER AND CALCIUM CHANNEL BLOCKER

2011 ◽  
Vol 29 ◽  
pp. e551
Author(s):  
B. Boyaci ◽  
P. Kizilirmak ◽  
M. Berktas
Keyword(s):  
Blood Pressure ◽  
Angiotensin Receptor Blocker ◽  
Channel Blocker ◽  
Pressure Control ◽  
Fixed Dose ◽  
Angiotensin Receptor ◽  
Single Pill ◽  
Dose Combination ◽  
Initial Blood ◽  
Initial Blood Pressure

scholarly journals The impact of antihypertensives on kidney disease

F1000Research ◽  
2017 ◽  
Vol 6 ◽  
pp. 611 ◽  
Author(s):  
Diego F Marquez ◽  
Gema Ruiz-Hurtado ◽  
Luis Ruilope
Keyword(s):  
Blood Pressure ◽  
Kidney Disease ◽  
Angiotensin Receptor Blocker ◽  
Channel Blocker ◽  
Enzyme Inhibitor ◽  
New Drugs ◽  
Converting Enzyme ◽  
Angiotensin Receptor ◽  
Positive Data ◽  
The Impact

Arterial hypertension and chronic kidney disease (CKD) are intimately related. The control of blood pressure (BP) levels is strongly recommended in patients with CKD in order to protect the kidney against the accompanying elevation in global cardiovascular (CV) risk. Actually, the goal BP in patients with CKD involves attaining values <140/90 mmHg except if albuminuria is present. In this case, it is often recommended to attain values <130/80 mmHg, although some guidelines still recommend <140/90 mmHg. Strict BP control to values of systolic BP around 120 mmHg was recently shown to be safe in CKD according to data from the SPRINT trial, albeit more data confirming this benefit are required. Usually, combination therapy initiated with an angiotensin receptor blocker (ARB) or angiotensin-converting enzyme inhibitor (ACEi) and commonly followed by the addition of a calcium channel blocker and a diuretic is needed. Further studies are required as well as new drugs in particular after the positive data obtained from new oral anti-diabetic drugs.

Differential blood pressure reductions by angiotensin receptor blocker plus calcium channel blocker or diuretic in elderly hypertension with or without obesity

2012 ◽  
Vol 6 (6) ◽  
pp. 393-398 ◽  
Author(s):  
Johji Kato ◽  
Naoto Yokota ◽  
Noboru Tamaki ◽  
Sumito Kariya ◽  
Toshihiro Kita ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Calcium Channel ◽  
Calcium Channel Blocker ◽  
Angiotensin Receptor Blocker ◽  
Channel Blocker ◽  
Receptor Blocker ◽  
Angiotensin Receptor

scholarly journals Achieving Blood Pressure Control with Telmisartan and Fixed Dose Combination of Telmisartan and Hydrochlorothiazide

2016 ◽  
Vol 11 (10-11) ◽  
pp. 598-601
Author(s):  
Anja Zaletel ◽  
Polona Knavs Vrhunec ◽  
Breda Barbič-Žagar
Keyword(s):  
Blood Pressure ◽  
Blood Pressure Control ◽  
Pressure Control ◽  
Fixed Dose Combination ◽  
Fixed Dose ◽  
Dose Combination

scholarly journals What do we Mean by “Ideal” Blood Pressure Control?

Kardiologiia ◽  
2021 ◽  
Vol 61 (7) ◽  
pp. 68-78
Author(s):  
O. D. Ostroumova ◽  
A. I. Kochetkov ◽  
N. A. Arablincky ◽  
N. A. Shatalova ◽  
R. R. Romanovsky ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Antihypertensive Drugs ◽  
Real Life ◽  
Cognitive Disorders ◽  
Pressure Control ◽  
Fixed Dose ◽  
Cerebrovascular Complications ◽  
Dose Combination ◽  
Numerous Data ◽  
Cognitive Disorders And Dementia

Arterial hypertension (AH) is one of the most important risk factors for development of myocardial infarction, chronic heart failure, stroke, cognitive disorders and dementia, and chronic kidney disease. Currently, special attention is paid to increased blood pressure variability (BPV) as a new risk factor for development of cardiovascular and cerebrovascular complications. The available evidence-based body of clinical studies demonstrates the importance of reducing not only the blood pressure itself but also the increased BPV to provide significant improvement of the prognosis and limits the risk of complications. This notion has been validated in consensus documents on the management of patients with AH. Among antihypertensive drugs, the fixed-dose combination (FC) amlodipine/perindopril has demonstrated a unique capability for reducing all types of BPV (visit-to-visit, day-to-day, during 24 h). According to current clinical guidelines, this combination belongs to first-line FCs indicated for most patients with AH. A distinctive feature of the FC amlodipine/perindopril is numerous data from real-life clinical practice, which support both its high antihypertensive efficacy and the ability to decrease high BPV. Therefore, the FC amlodipine/perindopril can be recommended for a broad range of AH patients to achieve BP control and to improve the prognosis.

HIGH-RISK HYPERTENSIVE PATIENTS: ASSESSMENT OF BLOOD PRESSURE CONTROL, ADHERENCE TO FIXED-DOSE COMBINATION TREATMENTS AND SATISFACTION: PP.5.201

2010 ◽  
Vol 28 ◽  
pp. e108
Author(s):  
MA Prieto Diaz ◽  
JA Divison Garrote ◽  
J Abellan Aleman ◽  
JL Llisterri Caro ◽  
NR Robles P&;eacute;rez-Monteoliva ◽  
...  
Keyword(s):  
Blood Pressure ◽  
High Risk ◽  
Blood Pressure Control ◽  
Pressure Control ◽  
Fixed Dose Combination ◽  
Fixed Dose ◽  
Hypertensive Patients ◽  
Combination Treatments ◽  
Dose Combination
Sign in / Sign up

Export Citation Format

Share Document